JP2010525813A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525813A5
JP2010525813A5 JP2010506206A JP2010506206A JP2010525813A5 JP 2010525813 A5 JP2010525813 A5 JP 2010525813A5 JP 2010506206 A JP2010506206 A JP 2010506206A JP 2010506206 A JP2010506206 A JP 2010506206A JP 2010525813 A5 JP2010525813 A5 JP 2010525813A5
Authority
JP
Japan
Prior art keywords
oligonucleotide strand
nucleotides
nucleic acid
length
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010506206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525813A (ja
Filing date
Publication date
Priority claimed from US11/797,216 external-priority patent/US20070265220A1/en
Application filed filed Critical
Publication of JP2010525813A publication Critical patent/JP2010525813A/ja
Publication of JP2010525813A5 publication Critical patent/JP2010525813A5/ja
Pending legal-status Critical Current

Links

JP2010506206A 2007-05-01 2008-04-11 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための、方法及び組成物 Pending JP2010525813A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/797,216 US20070265220A1 (en) 2004-03-15 2007-05-01 Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
PCT/US2008/004726 WO2008136902A1 (en) 2007-05-01 2008-04-11 Methods and compositions for the specific inhibition of gene expression by double-stranded rna

Publications (2)

Publication Number Publication Date
JP2010525813A JP2010525813A (ja) 2010-07-29
JP2010525813A5 true JP2010525813A5 (OSRAM) 2011-11-17

Family

ID=39944357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506206A Pending JP2010525813A (ja) 2007-05-01 2008-04-11 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための、方法及び組成物

Country Status (9)

Country Link
US (11) US20070265220A1 (OSRAM)
EP (1) EP2155772A4 (OSRAM)
JP (1) JP2010525813A (OSRAM)
CN (1) CN101848923A (OSRAM)
AU (1) AU2008246307A1 (OSRAM)
BR (1) BRPI0811475A2 (OSRAM)
CA (1) CA2685453A1 (OSRAM)
WO (1) WO2008136902A1 (OSRAM)
ZA (1) ZA200908342B (OSRAM)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2280826T5 (es) * 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
US7892793B2 (en) * 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
ATE485394T1 (de) * 2003-06-02 2010-11-15 Univ Massachusetts Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
US7750144B2 (en) * 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
AU2004248136B2 (en) 2003-06-02 2011-09-15 University Of Massachusetts Methods and compositions for controlling efficacy of RNA silencing
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
EP2821085B1 (en) * 2003-09-12 2020-04-29 University of Massachusetts Rna interference for the treatment of gain-of-function disorders
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
US20070265220A1 (en) * 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
JP5243789B2 (ja) * 2004-03-15 2013-07-24 シティ・オブ・ホープ 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物
EP1937066A4 (en) 2005-08-18 2008-12-24 Alnylam Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES
HUE037173T2 (hu) 2006-08-08 2018-08-28 Univ Bonn Rheinische Friedrich Wilhelms 5'-Foszfát-oligonukleotidok szerkezete és alkalmazása
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
TWI455944B (zh) 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
WO2010021720A1 (en) 2008-08-19 2010-02-25 Nektar Therapeutics Conjugates of small-interfering nucleic acids
US8225729B2 (en) * 2008-12-16 2012-07-24 Kimberly-Clark Worldwide, Inc. Three-dimensional wiping substrate and method therefor
CN105907756A (zh) * 2008-12-18 2016-08-31 戴瑟纳制药公司 延长的dicer酶底物和特异性抑制基因表达的方法
US11414664B2 (en) 2008-12-18 2022-08-16 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
WO2010111471A2 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2756845B1 (en) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
KR101791702B1 (ko) 2009-04-03 2017-10-30 다이서나 파마수이티컬, 인크. 비대칭 이중가닥 ｒｎａ에 의한 ｋｒａｓ의 특이적 저해를 위한 방법 및 조성물
CA2762524A1 (en) * 2009-05-18 2011-01-13 Ensysce Biosciences, Inc. Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
WO2010141933A1 (en) * 2009-06-05 2010-12-09 Dicerna Pharmaceuticals, Inc. Specific inhibition of gene expression by nucleic acid containing a dicer substrate
CN107129998A (zh) 2009-06-10 2017-09-05 淡马锡生命科学研究院有限公司 用于棉花中基因功能性分析的病毒诱导的基因沉默(vigs)
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011011447A1 (en) 2009-07-20 2011-01-27 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus gene expression
WO2011035065A1 (en) 2009-09-17 2011-03-24 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
US9222086B2 (en) 2009-09-23 2015-12-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
ES2562499T3 (es) 2009-12-09 2016-03-04 Nitto Denko Corporation Modulación de la expresión de HSP47
WO2011072292A2 (en) * 2009-12-11 2011-06-16 Dicerna Pharmaceuticals, Inc. Phase changing formulations of rna and rna derivatives
JP5257796B2 (ja) * 2009-12-28 2013-08-07 株式会社村田製作所 固体電解コンデンサ素子及びその製造方法
EP2591104A4 (en) 2010-07-06 2014-09-03 Dicerna Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR SPECIFIC INHIBITION OF THE ANDROGEN RECEPTOR BY DOUBLE-STRUCTURED RNA
JP5976643B2 (ja) 2010-07-06 2016-08-24 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
WO2012056440A1 (en) * 2010-10-28 2012-05-03 Nanodoc Ltd. COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
SG192961A1 (en) 2011-03-03 2013-09-30 Quark Pharmaceuticals Inc Compositions and methods for treating lung disease and injury
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
SG10201604726YA (en) 2011-06-10 2016-07-28 Temasek Life Sciences Lab Ltd Genetic manipulation and expression systems for pucciniomycotina and ustilaginomycotina subphyla
WO2012173994A2 (en) * 2011-06-15 2012-12-20 Dicerna Pharmaceuticals, Inc. Phase changing formulations of nucleic acid payloads
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013059496A1 (en) 2011-10-18 2013-04-25 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
KR20250133484A (ko) 2011-11-18 2025-09-05 알닐람 파마슈티칼스 인코포레이티드 변형된 ＲＮＡｉ 제제
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
WO2013126803A1 (en) 2012-02-24 2013-08-29 Protiva Biotherapeutics Inc. Trialkyl cationic lipids and methods of use thereof
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10100321B2 (en) 2012-04-19 2018-10-16 Temasek Life Sciences Laboratory Limited Methods for increasing cotton fiber length
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
JP2016501533A (ja) 2012-12-14 2016-01-21 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 二本鎖ｒｎａによるｃｋａｐ５の特異的阻害に関する方法および組成物
KR102205278B1 (ko) 2013-03-14 2021-01-22 다이서나 파마수이티컬, 인크. 음이온성 약제를 제형화하는 방법
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2905257T3 (es) 2013-07-03 2022-04-07 Dicerna Pharmaceuticals Inc Métodos y composiciones para la inhibición específica de alfa-1 antitripsina mediante ARN bicatenario
WO2015020960A1 (en) 2013-08-09 2015-02-12 Novartis Ag Novel lncrna polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
WO2015085158A1 (en) 2013-12-06 2015-06-11 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna
AU2014369850B2 (en) 2013-12-27 2021-04-08 Novo Nordisk A/S Methods and compositions for the specific inhibition of Glycolate Oxidase (HAO1) by double-stranded RNA
DK3204497T3 (da) 2014-10-10 2020-05-25 Dicerna Pharmaceuticals Inc Terapeutisk hæmning af lactatdehydrogenase og midler dertil
SG11201703132UA (en) 2014-10-22 2017-05-30 Temasek Life Sciences Lab Ltd Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
US10036017B2 (en) 2015-02-17 2018-07-31 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
WO2016183009A2 (en) 2015-05-08 2016-11-17 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna
CN114224907A (zh) * 2015-07-02 2022-03-25 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
HUE059718T2 (hu) 2016-09-02 2022-12-28 Dicerna Pharmaceuticals Inc 4'-foszfát analógok és azokat tartalmazó oligonukleotidok
WO2019074071A1 (ja) * 2017-10-11 2019-04-18 日東電工株式会社 核酸分子発現の調節
JP7308213B2 (ja) 2017-10-13 2023-07-13 ノヴォ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｌｄｈａの発現を阻害するための方法及び組成物
SG11202003488WA (en) 2017-10-20 2020-05-28 Dicerna Pharmaceuticals Inc Methods for treating hepatitis b infection
US11813280B2 (en) 2018-01-05 2023-11-14 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
KR20200109311A (ko) 2018-01-16 2020-09-22 다이서나 파마수이티컬, 인크. Aldh2 발현을 억제하기 위한 조성물 및 방법
US20210205264A1 (en) 2018-09-04 2021-07-08 H. Lee Moffitt Cancer Center & Research Institute Inc. Use of delta-tocotrienol for treating cancer
US11452738B2 (en) 2019-01-04 2022-09-27 Empirico Inc. Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
MX2021009754A (es) 2019-02-12 2021-09-08 Dicerna Pharmaceuticals Inc Metodos y composiciones para inhibir la expresion de cyp27a1.
WO2020205473A1 (en) 2019-03-29 2020-10-08 Decerna Pharmaceuticals, Inc. Compositions and methods for the treatment of kras associated diseases or disorders
CA3135402A1 (en) 2019-04-04 2020-10-08 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
CN113795581A (zh) 2019-05-03 2021-12-14 迪克纳制药公司 具有缩短的有义链的双链核酸抑制剂分子
WO2021041756A1 (en) 2019-08-30 2021-03-04 Dicerna Pharmaceuticals, Inc. Ligand-2'-modified nucleic acids, synthesis thereof and intermediate compounds thereof
WO2021067744A1 (en) 2019-10-02 2021-04-08 Dicerna Pharmaceuticals, Inc. Chemical modifications of small interfering rna with minimal fluorine content
WO2021130270A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
CA3163490A1 (en) 2019-12-24 2021-07-01 F. Hoffman-La Roche Ag Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
MX2022011550A (es) 2020-03-18 2023-01-04 Dicerna Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión de angptl3.
MX2023001541A (es) 2020-08-04 2023-03-08 Dicerna Pharmaceuticals Inc Administracion sistemica de oligonucleotidos.
AU2021321430A1 (en) 2020-08-04 2023-03-02 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting PLP1 expression
TW202221120A (zh) 2020-08-04 2022-06-01 美商黛瑟納製藥公司 用於治療代謝症候群之組成物及方法
IL300338A (en) 2020-08-05 2023-04-01 Dicerna Pharmaceuticals Inc Compounds and methods for inhibiting the expression of LPA
TW202221122A (zh) 2020-08-05 2022-06-01 瑞士商赫孚孟拉羅股份公司 Ｂ型肝炎患者之寡核苷酸治療
CA3214439A1 (en) 2021-04-12 2022-10-20 Boehringer Ingelheim International Gmbh Compositions and methods for inhibiting ketohexokinase (khk)
WO2022221430A1 (en) 2021-04-14 2022-10-20 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating pnpla3 expression
WO2022223515A2 (en) 2021-04-19 2022-10-27 Novo Nordisk A/S Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
AR125992A1 (es) 2021-05-28 2023-08-30 Novo Nordisk As Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1)
US20230107967A1 (en) 2021-08-25 2023-04-06 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting alpha-1 antitrypsin expression
KR20240101580A (ko) 2021-11-11 2024-07-02 에프. 호프만-라 로슈 아게 Hbv 치료를 위한 약학 조합물
TW202330920A (zh) 2021-12-01 2023-08-01 美商戴瑟納製藥股份有限公司 用於調節ａｐｏｃ３表現之組合物及方法
US20230374522A1 (en) 2022-04-15 2023-11-23 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating scap activity
AU2023269281A1 (en) 2022-05-12 2024-10-10 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting mapt expression
IL316843A (en) 2022-05-13 2025-01-01 Dicerna Pharmaceuticals Inc Compounds and methods for inhibiting SNCA deactivation
TWI868755B (zh) 2022-06-24 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
WO2024040041A1 (en) 2022-08-15 2024-02-22 Dicerna Pharmaceuticals, Inc. Regulation of activity of rnai molecules
TW202430637A (zh) 2022-11-16 2024-08-01 美商戴瑟納製藥股份有限公司 Stat3靶向性寡核苷酸及其用途
WO2025029625A1 (en) 2023-07-28 2025-02-06 Dicerna Pharmaceuticals, Inc. Compositions and methods for programmed death ligand receptor (pd-l1) expression
WO2025054459A1 (en) 2023-09-08 2025-03-13 Dicerna Pharmaceuticals, Inc. Rnai oligonucleotide conjugates
WO2025133951A1 (en) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
KR100414936B1 (ko) * 1997-09-12 2004-01-13 엑시콘 에이/에스 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO2000044914A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
WO2000063364A2 (en) * 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
KR20020030780A (ko) 1999-07-09 2002-04-25 이곤 이 버그 플라스미드 서열의 전사 동안 비정상적인 ｒｎａ 형성을예방하기 위한 방법 및 조성물
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US20050032733A1 (en) * 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050233329A1 (en) * 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. Inhibition of gene expression using duplex forming oligonucleotides
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US8202846B2 (en) * 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
EP1309726B2 (en) * 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
AU9166901A (en) 2000-07-10 2002-01-21 Aloys Wobben Device for handling unit loads
RU2322500C2 (ru) * 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
EP1229134A3 (en) * 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
CA2526831C (en) 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20050079610A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20060287267A1 (en) * 2001-05-18 2006-12-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
ES2566561T3 (es) * 2001-07-12 2016-04-13 University Of Massachusetts Producción in vivo de ARN pequeños de interferencia que median el silenciamiento génico
US7527945B2 (en) * 2001-10-22 2009-05-05 Nucleonics, Inc. Transfection kinetics and structural promoters
WO2003046173A1 (en) * 2001-11-28 2003-06-05 Center For Advanced Science And Technology Incubation, Ltd. siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
DE10202419A1 (de) * 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP2221377B2 (en) * 2002-02-01 2017-05-17 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
EP1495141A4 (en) 2002-03-20 2006-03-22 Massachusetts Inst Technology THERAPY OF HIV
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
US6890719B2 (en) 2002-05-10 2005-05-10 The Board Of Trustess Of The University Of Illinois Fluorescence based biosensor
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
CA2884658A1 (en) 2002-07-26 2004-02-05 Novartis Vaccines And Diagnostics, Inc. Modified small interfering rna molecules and methods of use
EP1540004A4 (en) * 2002-07-31 2007-10-03 Nucleonics Inc DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF
ES2280826T5 (es) * 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
ES2665274T5 (es) * 2002-08-05 2021-06-30 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
WO2004014933A1 (en) * 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
WO2004027030A2 (en) * 2002-09-18 2004-04-01 Isis Pharmaceuticals, Inc. Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds
WO2004029215A2 (en) 2002-09-26 2004-04-08 The Regents Of The University Of California Conditional gene expression using rnai
AU2003284323A1 (en) 2002-10-18 2004-05-04 Alnylam Pharmaceuticals Inc Double-stranded rna structures and constructs, and methods for generating and using the same
EP1560840B1 (en) * 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US20040248299A1 (en) * 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
WO2004065600A2 (en) * 2003-01-17 2004-08-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference by palindromic or modified rna molecules
EP1597351B1 (en) 2003-02-27 2012-04-18 Alnylam Pharmaceuticals Inc. METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES
US20040224405A1 (en) * 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
US7750144B2 (en) * 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
BRPI0411219A (pt) 2003-06-12 2006-07-18 Nucleonics Inc seqüências de hbv e hcv conservadas úteis para silenciamento de gene
WO2005040388A2 (en) 2003-08-22 2005-05-06 Nucleonics Inc. Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
GB0323270D0 (en) 2003-10-04 2003-11-05 Bodycage Ltd Stirrup
US20070265220A1 (en) * 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
JP5243789B2 (ja) * 2004-03-15 2013-07-24 シティ・オブ・ホープ 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
CA2568735A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
JP4991547B2 (ja) * 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法

Similar Documents

Publication Publication Date Title
JP2010525813A5 (OSRAM)
EP3464634B1 (en) Molecular tagging methods and sequencing libraries
JP2011502502A5 (OSRAM)
JP2022023213A5 (OSRAM)
NZ598943A (en) Hbv antisense inhibitors
WO2005089287A3 (en) Methods and compositions for the specific inhibition of gene expression by double-stranded rna
JP2017093448A5 (OSRAM)
JP2006526394A5 (OSRAM)
JP2008283975A5 (OSRAM)
RU2017117510A (ru) Редактирование целевой рнк
JP2007532100A5 (OSRAM)
JP2011500092A5 (OSRAM)
JP2007503474A5 (OSRAM)
JP2005517452A5 (OSRAM)
JP2019518476A (ja) 等温核酸自己増幅法
JP2012507984A5 (OSRAM)
JP2012514451A5 (OSRAM)
WO2010090857A3 (en) Methods for amplifying hepatitis c virus nucleic acids
WO2005049851A3 (en) Methods, articles, and compositions for identifying oligonucleotides
CN104726549A (zh) 一种基于切刻酶的双链核酸等温扩增检测新方法
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
JP2011512153A5 (OSRAM)
Wulf et al. Chemical capping improves template switching and enhances sequencing of small RNAs
Xu et al. TGIRT-seq protocol for the comprehensive profiling of coding and non-coding RNA biotypes in cellular, extracellular vesicle, and plasma RNAs
JP6069314B2 (ja) 長鎖核酸分子の大規模合成方法